# Adamis Issues Nationwide Voluntary Recall of Symjepi® (Epinephrine) Injection for Potential Manufacturing Defect

Date: 03/22/2022

At Magellan Rx Management, we want to help you get the best possible care. We have created a site to share drug recall information.

Adamis Pharmaceuticals has posted a lot recall of Symjepi (epinephrine) Injection.

**About this recall:**
Adamis is voluntarily recalling certain lots of Symjepi (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) prefilled single-dose syringes to the consumer level. The batches (lots) in the table on the following page are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes Symjepi in the United States (US), under license from Adamis.

**What this means to you:**
If a person is experiencing an allergic reaction and/or anaphylaxis and is unable to access life-saving epinephrine due to the syringe malfunction, it can lead to life threatening consequences including death. Although not confirmed to be related to the recall, there have been two different customer complaints on three syringes, regarding difficulty in dispensing the product, to date. However, neither US WorldMeds nor Adamis Pharmaceuticals has received, or is aware of, any adverse events related to this recall.

Symjepi is used for the emergency treatment of allergic reactions including anaphylaxis to stinging insects (bees, wasps, hornets, yellow jackets, and fire ants) and biting insects (mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as anaphylaxis of unknown cause and exercise-induced anaphylaxis.

The products are packaged in 2-count prefilled single-dose syringes per carton and were distributed nationwide in the US. The products can be identified by the label containing the US WorldMeds name and logo pictured on the cartons linked on the following page at the FDA Recall Notification and by the NDCs, lot numbers, and expiration dates shown in the table on the following page.

Consumers that have products that are subject to this recall should stop using the products immediately and may either return or discard the recalled lots. Consumers with questions regarding this recall can call (888) 900-8796 or e-mail questions at medinfo@usworldmeds.com Monday through Friday from 8:00 am to 4:00 pm ET.

The recall encompasses all of the following batches, within expiry:

| Product | Strength | NDC | Lot | Expiration |
|---|---|---|---|---|
| Symjepi (epinephrine) Injection | 0.15 mg/0.3 mL | 78670-0131-02 | 21101Y | 11/30/2022 |
| | 0.3 mg/0.3 mL | 78670-0130-02 | 21041W | 8/31/2022 |
| | | | 21081W | 11/30/2022 |
| | | | 21102W | 2/28/2023 |

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

For more information regarding this FDA Recall Notification, please refer to the FDA website: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection

FDA contact information for reporting adverse events/quality complaints can be reached online at https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home or by calling the FDA at 1-888-INFO-FDA (1-888-463-6332) and then selecting prompt #2.